Hepion Pharmaceuticals Files 8-K: Material Agreement & Equity Sales
Ticker: CTRVP · Form: 8-K · Filed: May 6, 2025 · CIK: 1583771
| Field | Detail |
|---|---|
| Company | Hepion Pharmaceuticals, Inc. (CTRVP) |
| Form Type | 8-K |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale
Related Tickers: HEPA
TL;DR
Hepion (HEPA) filed an 8-K for a material agreement and unregistered equity sales on April 30th.
AI Summary
Hepion Pharmaceuticals, Inc. announced on April 30, 2025, that it entered into a Material Definitive Agreement and also disclosed Unregistered Sales of Equity Securities. The company, formerly known as ContraVir Pharmaceuticals, Inc., is incorporated in Delaware and has its principal executive offices in Morristown, NJ.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and the issuance of equity, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves unregistered sales of equity, which can sometimes signal dilution or financial distress, and a material definitive agreement, the terms of which are not fully disclosed in this summary.
Key Players & Entities
- Hepion Pharmaceuticals, Inc. (company) — Registrant
- ContraVir Pharmaceuticals, Inc. (company) — Former company name
- April 30, 2025 (date) — Date of earliest event reported
- 001-36856 (other) — SEC File Number
- 46-2783806 (other) — IRS Identification No.
FAQ
What is the nature of the Material Definitive Agreement?
The filing indicates the entry into a Material Definitive Agreement, but the specific details of this agreement are not provided in the summary information.
What were the terms of the Unregistered Sales of Equity Securities?
The filing notes Unregistered Sales of Equity Securities, but the details regarding the number of shares, price, or purchasers are not specified in the provided summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 30, 2025.
What is Hepion Pharmaceuticals, Inc.'s former company name?
Hepion Pharmaceuticals, Inc.'s former company name was ContraVir Pharmaceuticals, Inc.
Where are Hepion Pharmaceuticals, Inc.'s principal executive offices located?
Hepion Pharmaceuticals, Inc.'s principal executive offices are located at 55 Madison Ave., Suite 400-PMB# 4362, Morristown, NJ 07960.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Hepion Pharmaceuticals, Inc. (CTRVP).